Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm

RT @BatistaTP: @BoriaFelix @SoMe4SurgeryPr1 @me4_so @GynMe4 @JAMASurgery https://t.co/fTCnJ2PlGR

RT @BatistaTP: @BoriaFelix @SoMe4SurgeryPr1 @me4_so @GynMe4 @JAMASurgery https://t.co/fTCnJ2PlGR

RT @BatistaTP: @BoriaFelix @SoMe4SurgeryPr1 @me4_so @GynMe4 @JAMASurgery https://t.co/fTCnJ2PlGR

RT @BatistaTP: @BoriaFelix @SoMe4SurgeryPr1 @me4_so @GynMe4 @JAMASurgery https://t.co/fTCnJ2PlGR

@BoriaFelix @SoMe4SurgeryPr1 @me4_so @GynMe4 @JAMASurgery https://t.co/fTCnJ2PlGR

RT @aakonc: @CDTzeng @RSnyder_MD @NabeelZafarMD @JAMASurgery @JAMANetwork @TaylorJolyn @HopSTranCao @mkatzmd @SurenaMatinMD In gyn on surge…

RT @aakonc: @CDTzeng @RSnyder_MD @NabeelZafarMD @JAMASurgery @JAMANetwork @TaylorJolyn @HopSTranCao @mkatzmd @SurenaMatinMD In gyn on surge…

@CDTzeng @RSnyder_MD @NabeelZafarMD @JAMASurgery @JAMANetwork @TaylorJolyn @HopSTranCao @mkatzmd @SurenaMatinMD In gyn on surgery there is good data to support DOAC (apixaban) as an alternative that pts prefer https://t.co/iKz12IyPqQ.

@TaylorJolyn @CDTzeng @RSnyder_MD @NabeelZafarMD @JAMASurgery @JAMANetwork @HopSTranCao @mkatzmd @SurenaMatinMD Yep, I was thinking of the same study: https://t.co/gBcKP7tH6O

RT @aakonc: One of the most common qs I get re #VTE prophylaxis is whether safe to use DOACs in post op setting. However, until this paper…

@MaxKates @angiesmith_uro @brady_urology @JHBladderCancer @kafarling Interesting trial from the gyn onc literature, opportunity for cystectomy or so we assume it'll essentially be the same? https://t.co/gSUFER0wa0

RT @amarantac: Trial I was referring to ⁦@GBarnesMD⁩ - thx for great #gyoedu lecture! Safety and Efficacy of Apixaban vs Enoxaparin for Pre…

RT @Bhandoria: @drsadiejones @IndiraRosero @Aarti2008 @ARGO_COL @BGCS_org Here you go..@ASCO_pubs @NEJM @JAMA_current @IJGCfellows @IJGConl…

@drsadiejones @IndiraRosero @Aarti2008 @ARGO_COL @BGCS_org Here you go..@ASCO_pubs @NEJM @JAMA_current @IJGCfellows @IJGConline @ESGO_society @ENYGO_official https://t.co/jlkjp7NRjM https://t.co/s2kzAJZyls https://t.co/Ss61xUdMZp

@drsadiejones Yes and patients are happier. https://t.co/0HbW6JG5XW

New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: Randomized Clinical Trial https://t.co/5eHdWbhrif

New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: Randomized Clinical Trial https://t.co/5eHdWbhrif

New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: Randomized Clinical Trial https://t.co/5eHdWbhrif

New findings from CU Cancer Center member Dr. Guntupalli and his team suggest that oral apixaban may offer a safe alternative to subcutaneous enoxaparin that is easier and less painful for patients to take. @JAMA_current #cancerresearch #gynecologiccancers

@jgrif17 @HopSTranCao @SyedAAhmad5 @TheNotoriousHPB @DenboJw @JHawksworthMD @HoggNDMD @DrNCoburn Yep and the Gyn Onc literature Same efficacy and risks of bleeding events etc. Some concerns this trial may be underpowered but I know for an equivalency trial

New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: Randomized Clinical Trial https://t.co/5eHdWbhrif

RT @tripdatabase: New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Underg…

New2Trip: Safety & Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: Randomized Clinical Trial https://t.co/5eHdWbhrif

RT @JAMANetworkOpen: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/WcnL…

#DOAC #LMWH and gynecologic cancer #cardiotwitter

【婦人科】 婦人科系癌の手術後の血栓予防薬として、アピキサバンの経口投与は、標準治療であるエノキサパリンの皮下投与と比較し、安全性が高く、痛みが少なく、服用しやすい可能性があることが示唆された。 RCT PMID:32589230 https://t.co/ypyNkTup3a

Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/WcnLbBIxSB #MostRead

RT @FBackesMD: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/ClkICxcPOy…

RT @FBackesMD: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/ClkICxcPOy…

Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/ClkICxcPOy via @JAMANetworkOpen part of @JAMANetwork : great debate at journal club tonight

Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/EZcUfzd7ka #MostRead

@GBarnesMD @MarcCarrier1 @connors_md @Cihan_Ay_MD @gary_lyman @AggieLeeMD @isth @ASH_hematology @ASCO Agree thought it was a nicely done study. My original thoughts here https://t.co/0qU4IrflJp

Étude suggèrant que l’apixaban serait une alternative sure à l’énoxaparine pour la thromboprophylaxie chez les femmes subissant une chirurgie pour un cancer gynécologique https://t.co/jombhtoYqg

However, I had not yet seen this @JAMANetworkOpen paper when I put the talk together: https://t.co/qAncxAO1x5. Thanks to @amarantac for highlighting it to me at the end of the talk.

@uppals Be sure to check out this article after you watch the talk. @amarantac pointed it out - very relevant! https://t.co/qAncxAO1x5

Trial I was referring to ⁦@GBarnesMD⁩ - thx for great #gyoedu lecture! Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm https://t.co/iDT9dzENjc

Apixaban BID was found to be safe for Gyn Onc pts w/ no difference in VTE (vs. lovenox). Pts report ⬆️ satisfaction (no surprise). Oral AC --> better adherence, maybe ⬇️ cost? Will this change your practice? @DrSamarNahas1 @temkins #MedTwitter http

@jmv_nguyen @IJGConline @IJGCfellows @uoftobgyn @Sunnybrook is 5% w/o any prophylaxis or w/ single prophylaxis? Also, check out this RCT (but not dual prophylaxis). @JAMAOnc @IJGCfellows @IJGConline https://t.co/zNPWh7l4g8

RT @Kmtheisen1: RCT data supporting role of apixaban in post surgical VTE prophylaxis (vs lovenox). No difference in VTE prevention or majo…

RT @Kmtheisen1: RCT data supporting role of apixaban in post surgical VTE prophylaxis (vs lovenox). No difference in VTE prevention or majo…

RCT data supporting role of apixaban in post surgical VTE prophylaxis (vs lovenox). No difference in VTE prevention or major bleeding events. But patient satisfaction higher with oral therapy. https://t.co/A1Fdz5dxX3

I know many patients who would appreciate oral VTE prophylaxis over a self-administered injection after going home!

Great to have data for oral anticoagulants in gyn onc patients. @sgo.org @SHAREing

RT @StephanieVBlank: Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing…

RT @StephanieVBlank: Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing…

RT @StephanieVBlank: Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing…

Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial https://t.co/6kwaiWT0sf

The end of the “lovenox teaching” order prior to discharge?!?!?

RT @womenofteal: Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surg…

RT @womenofteal: Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surg…

Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant NeoplasmA Randomized Clinical Trial https://t.co/lUWlqSgRK5 #gyncsm #OncoAlert

RT @rincondesisifo: (JAMA) Apixabán vs enoxaparina en la prevención del TEV postquirúrgico en pac con tumores ginecológicos https://t.co/pk…

https://t.co/jXoNRpqzmx

Apixaban versus enoxaparin in Gynecologic malignancies. https://t.co/i2KPDRzuM0

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

Buenas noticias🙂! - inyecciones 💉 = + adherencia 💊! Oral apixaban is a potentially safe, less painful, and easier-to-take alternative to subcutaneous enoxaparin for thromboprophylaxis after surgery for gynecologic cancer. https://t.co/crKMuhUc0Q

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @macesari: Evidence supporting the hypothesis that taking a pill (#apixaban) is less painful than receiving an injection (enoxaparin) @…

RT @macesari: Evidence supporting the hypothesis that taking a pill (#apixaban) is less painful than receiving an injection (enoxaparin) @…

RT @macesari: Evidence supporting the hypothesis that taking a pill (#apixaban) is less painful than receiving an injection (enoxaparin) @…

RT @macesari: Evidence supporting the hypothesis that taking a pill (#apixaban) is less painful than receiving an injection (enoxaparin) @…

Evidence supporting the hypothesis that taking a pill (#apixaban) is less painful than receiving an injection (enoxaparin) @JAMANetworkOpen #Medicine #Science #Research https://t.co/cor1PuuNcG

Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial | Oncology | JAMA Network Open | JAMA Network ⁦@JAMAOnc⁩ https://

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

Apixaban oral más seguro, menos doloroso y más fácil de tomar q enoxaparina subcutánea para tromboprofilaxis desp cirugía por cáncer ginecológico. Se postula que apixaban para prevenir eventos tromboembólicos venosos sería equivalente a enoxaparina https:/

Apixaban vs. Enoxaparin for the prevention of VTE after gynecologic surgery for cancer https://t.co/hZ6wXbXAJZ Groups did not differ for VTE or bleeding events Better patient satisfaction in the Apixaban group That's interesting 👀

RT @ovarcome: Study by our Leadership Council Member, Dr. Saketh Guntupalli from @CUMedicalSchool. #Ovarcome https://t.co/RnPCAK25eK

RT @ovarcome: Study by our Leadership Council Member, Dr. Saketh Guntupalli from @CUMedicalSchool. #Ovarcome https://t.co/RnPCAK25eK

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

Study by our Leadership Council Member, Dr. Saketh Guntupalli from @CUMedicalSchool. #Ovarcome https://t.co/RnPCAK25eK

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @aakonc: One of the most common qs I get re #VTE prophylaxis is whether safe to use DOACs in post op setting. However, until this paper…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @RobertoVargasMD: Apixaban instead of LMWH for DVT/PE prophy after gyn onc surgery? Yes please. No more lovenox teaching on day of di…

RT @aakonc: One of the most common qs I get re #VTE prophylaxis is whether safe to use DOACs in post op setting. However, until this paper…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @juanjolopezn: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer #VTE # cancer @JAMA_…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @aakonc: One of the most common qs I get re #VTE prophylaxis is whether safe to use DOACs in post op setting. However, until this paper…

@cordekroon I think there is one already, although not dual. Check this out https://t.co/zNPWh7l4g8

https://t.co/zNPWh7l4g8

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

@PharmDickerson

RT @MarcCarrier1: Apixaban vs Enoxaparin for Preventing Postoperative Thromboembolism in Women With Gynecologic Cancer https://t.co/0XNqNto…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…

RT @bhwords: Potential new use for apixaban: A trial of 28 days of low dose apixaban vs enoxaparin for Thromboprophylaxis in Women Under…